Helicobacter pylori infection presenting as childhood recurrent headache: A case report

Headache in children and adolescents is common and there is a steady increase in the incidences in recent years. Migraine has been attributed as the most common cause of recurrent headache under the age of 6 years. Migraine is reported in 3.9% of children aged 7–15 years which increases from 1.7% in 7 years old to 5.3% in 15 years old. Many studies have focussed on the association between headache and Helicobacter pylori infection which is acquired early in the childhood beyond the age of 10 years through fecal-oral route transmission. Here, we report a case of H. pylori infection in a 13-year-old female child who presented with a history of recurrent headache refractory to standard treatment. Later, the child was diagnosed to have H. pylori gastritis. Headache responded to 4 weeks course of H. pylori eradication therapy

From disabling shoulder pain to full functional gain: A hectic approach for higher yield

Idiopathic brachial neuritis also known as Parsonage-Turner syndrome is a well-defined but relatively uncommon clinical entity affecting young adults. It presents with acute-onset severe shoulder pain persisting from days to weeks along with associated weakness and subsequent atrophy of muscles of the shoulder girdle, leading to marked impairment of activities of daily living. Often, the diagnosis is late and sometimes missed in the vast ocean of its mimics. We report a case of idiopathic brachial plexus neuritis in a child, who was aggressively  investigated and promptly treated very early in the course of the disease, and subsequently, muscle atrophy was prevented. This case highlights the importance of picking up the disease amid its diagnostic dilemmas and managing proactively before it evolves along its natural course which may take months to years for complete, sometimes partial recovery

Early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy:a multicentre double-blind pilot randomised controlled trial

Objective: To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE). Design: Double-blind pilot randomised controlled trial.Setting: Eight neonatal units in South Asia. Patients: Neonates (≥36 weeks) with moderate or severe HIE admitted between 31 December 2022 and 3 May 2023. Interventions: Erythropoietin (500 U/kg daily) or to the placebo (sham injections using a screen) within 6 hours of birth and continued for 9 days. MRI at 2 weeks of age. Main outcomes and measures: Feasibility of randomisation, drug administration and assessment of brain injury using MRI. Results: Of the 154 neonates screened, 56 were eligible; 6 declined consent and 50 were recruited; 43 (86%) were inborn. Mean (SD) age at first dose was 4.4 (1.2) hours in erythropoietin and 4.1 (1.0) hours in placebo. Overall mortality at hospital discharge occurred in 5 (19%) vs 11 (46%) (p=0.06), and 3 (13%) vs 9 (40.9%) (p=0.04) among those with moderate encephalopathy in the erythropoietin and placebo groups. Moderate or severe injury to basal ganglia, white matter and cortex occurred in 5 (25%) vs 5 (38.5%); 14 (70%) vs 11 (85%); and 6 (30%) vs 2 (15.4%) in the erythropoietin and placebo group, respectively. Sinus venous thrombosis was seen in two (10%) neonates in the erythropoietin group and none in the control group. Conclusions: Brain injury and mortality after moderate or severe HIE are high in South Asia. Evaluation of erythropoietin monotherapy using MRI to examine treatment effects is feasible in these settings. Trial registration number: NCT05395195

CORRELATION OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE (NT PRO BNP) WITH SERUM FERRITIN AND NUMBER OF BLOOD TRANSFUSIONS IN THALASSEMIA PATIENTS-A CROSS-SECTIONAL STUDY

Objective: Thalassemia is a genetic disorder of globin chain production in which there is an imbalance between alpha globin and beta globin chain production. Thalassemia patients require frequent blood transfusions to maintain adequate tissue oxygenation, which can cause a state of iron overload. NT pro BNP is a sensitive biomarker to detect cardiac iron overload. Our objective of this study was to estimate the level of NTproBNP in beta-thalassemia patients and to find out the correlation of NT pro BNP with serum ferritin levels and the number of blood transfusions.Methods: 50 thalassemic patients aged below 18 y with no known cardiac comorbidities were enrolled in this cross-sectional study. The correlation between the levels of NT-pro BNP with serum ferritin and number of blood transfusions and chelation therapy was measured.Results: This study demonstrated that the levels of NT Pro BNP were elevated in thalassemia patients with a positive correlation with serum ferritin values and the number of blood transfusions which the patients received.Conclusion: This Study also concluded that NT Pro BNP can be used as a biochemical marker used to detect early stages of cardiac failure and also to identify patients going for heart failure, especially in resource-limited settings

Holt-oram syndrome associated with double outlet right ventricle: A rare association

Holt-Oram syndrome is a rare inherited disorder that causes abnormalities of the hands, arms, and the heart. Most commonly, there are defects in the carpal bones of the wrist and in the bones of the thumb along with cardiac defects such as atrial or ventricular septal defects. We report a case of Holt-Oram syndrome with a rare association of double outlet right ventricle

A phase III randomized, open-label, non-inferiority clinical trial comparing liquid and lyophilized formulations of oral live attenuated human rotavirus vaccine (HRV) in Indian infants

The human rotavirus vaccine (HRV; Rotarix, GSK) is available as liquid (Liq) and lyophilized (Lyo) formulations, but only Lyo HRV is licensed in India. In this phase III, randomized, open-label trial (NCT02141204), healthy Indian infants aged 6–10 weeks received 2 doses (1 month apart) of either Liq HRV or Lyo HRV. Non-inferiority of Liq HRV compared to Lyo HRV was assessed in terms of geometric mean concentrations (GMCs) of anti-RV immunoglobulin A (IgA), 1-month post-second dose (primary objective). Reactogenicity/safety were also evaluated. Seroconversion was defined as anti-RV IgA antibody concentration ≥20 units [U]/mL in initially seronegative infants (anti-RV IgA antibody concentration <20 U/mL) or ≥2-fold increase compared with pre-vaccination concentration in initially seropositive infants. Of the 451 enrolled infants, 381 (189 in Liq HRV and 192 in Lyo HRV group) were included in the per-protocol set. The GMC ratio (Liq HRV/Lyo HRV) was 0.93 (95% confidence interval [CI]: 0.65–1.34), with the lower limit of the 95% CI reaching ≥0.5, the pre-specified statistical margin for non-inferiority. In the Liq HRV and Lyo HRV groups, 42.9% and 44.3% (baseline) and 71.4% and 73.4% (1-month post-second dose) of infants had anti-RV IgA antibody concentration ≥20 U/mL, and overall seroconversion rates were 54.5% and 50.0%. Incidences of solicited and unsolicited adverse events were similar between groups and no vaccine-related serious adverse events were reported. Liq HRV was non-inferior to Lyo HRV in terms of antibody GMCs and showed similar reactogenicity/safety profiles, supporting the use of Liq HRV in Indian infants

Association of Scrub Typhus in Children with Acute Encephalitis Syndrome and Meningoencephalitis, Southern India.

Scrub typhus is an established cause of acute encephalitis syndrome (AES) in northern states of India. We systematically investigated 376 children with AES in southern India, using a stepwise diagnostic strategy for the causative agent of scrub typhus, Orientia tsutsugamushi, including IgM and PCR testing of blood and cerebrospinal fluid (CSF) to grade its association with AES. We diagnosed scrub typhus in 87 (23%) children; of those, association with AES was confirmed in 16 (18%) cases, probable in 55 (63%), and possible in 16 (18%). IgM detection in CSF had a sensitivity of 93% and specificity of 82% compared with PCR. Our findings suggest scrub typhus as an emerging common treatable cause of AES in children in southern India and highlight the importance of routine testing for scrub typhus in diagnostic algorithms. Our results also suggest the potential promise of IgM screening of CSF for diagnosis of AES resulting from scrub typhus

Early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy:a multicentre double-blind pilot randomised controlled trial

Objective: To examine the feasibility of early and extended erythropoietin monotherapy after hypoxic ischaemic encephalopathy (HIE). Design: Double-blind pilot randomised controlled trial.Setting: Eight neonatal units in South Asia. Patients: Neonates (≥36 weeks) with moderate or severe HIE admitted between 31 December 2022 and 3 May 2023. Interventions: Erythropoietin (500 U/kg daily) or to the placebo (sham injections using a screen) within 6 hours of birth and continued for 9 days. MRI at 2 weeks of age. Main outcomes and measures: Feasibility of randomisation, drug administration and assessment of brain injury using MRI. Results: Of the 154 neonates screened, 56 were eligible; 6 declined consent and 50 were recruited; 43 (86%) were inborn. Mean (SD) age at first dose was 4.4 (1.2) hours in erythropoietin and 4.1 (1.0) hours in placebo. Overall mortality at hospital discharge occurred in 5 (19%) vs 11 (46%) (p=0.06), and 3 (13%) vs 9 (40.9%) (p=0.04) among those with moderate encephalopathy in the erythropoietin and placebo groups. Moderate or severe injury to basal ganglia, white matter and cortex occurred in 5 (25%) vs 5 (38.5%); 14 (70%) vs 11 (85%); and 6 (30%) vs 2 (15.4%) in the erythropoietin and placebo group, respectively. Sinus venous thrombosis was seen in two (10%) neonates in the erythropoietin group and none in the control group. Conclusions: Brain injury and mortality after moderate or severe HIE are high in South Asia. Evaluation of erythropoietin monotherapy using MRI to examine treatment effects is feasible in these settings. Trial registration number: NCT05395195